Revvity Stock (RVTY)

XNYS Alert Compare

Health Care · Fundamental analysis

Revvity's revenue has shrunk by 5.5% a year over the last 5 years; the median of the Health Care sector is +8.5%. The net margin in the last fiscal year was 8.4%, the sector median 13.9%. The 52-week high is 18.3% away (close of Nov 20, 2026).

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

At a glance: figures and chart

2 strengths · 2 weaknesses · Fiscal year to Dec 28, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
  • Quality 3 of 6 criteria with data met · 2 without data
  • Growth 1 of 7 criteria with data met
  • Dividend 6 of 7 criteria with data met
  • Financial strength 5 of 5 criteria with data met · 1 without data
Chart position more than 10% above – position relative to the 200-day line

Strengths well above the threshold

  • Free cash flow margin 17.8% Threshold: above 10% · Distance +7.8 pp · Sector median 14.5% (61 stocks) · Fiscal year to Dec 28, 2025
  • Equity ratio 59.6% Threshold: above 30% · Distance +29.6 pp · Sector median 44.2% (63 stocks) · Fiscal year to Dec 28, 2025

Weaknesses well below the threshold

  • Return on equity 3.3% Threshold: above 15% · Distance −11.7 pp · Sector median 12.8% (54 stocks) · Fiscal year to Dec 28, 2025
  • Revenue growth 5 years −5.5% per year Threshold: above 5% per year · Distance −10.5 pp · Sector median +7.8% per year (60 stocks) · Fiscal year to Dec 28, 2025

On the radar

  • Position relative to the 200-day line: more than 10% above (as of Nov 19, 2026)
  • Net margin 8.4% – Threshold: above 10%, distance −1.6 pp (Fiscal year to Dec 28, 2025)

What we do not know

  • Data missing: 3 of 28 criteria not stated in the SEC filings (Fiscal year to Dec 28, 2025).
    • Gross margin above 40%
    • Free cash flow positive in each of the last 3 fiscal years
    • Piotroski F-Score at least 7 of 9

How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Revvity, formerly part of PerkinElmer, is a US provider for life sciences and diagnostics. The company supplies instruments, reagents and software for research and drug development as well as tests, for example for newborn screening. Customers are labs worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Laboratory instruments · Waltham, USA

Revvity offers technologies and services for research and diagnostics in healthcare. The company reports in segments for life sciences and diagnostics. For life sciences, it supplies reagents, antibodies, instruments and software for drug discovery. Customers are pharma, biotechnology, contract research organizations as well as universities and government institutes. Diagnostics supplies hospitals, medical laboratories and physicians with instruments, reagents and software. Its focus areas are screening around pregnancy and early childhood as well as immunodiagnostics, plus tests for infections.

Automatically summarized from SEC annual report (10-K, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Revvity

This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today −4.2%
  • 7 days −5.9%
  • 30 days −7.3%
  • 1 year +54.5%
Day range (last trading day)
−1.1%Price at 22% of the range+3.9%
52-week range
−44.1%Price at 71% of the range+18.3%
Distance from the all-time high
−28.5%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Chart analysis: trend by timeframe

  1. 1W weekly candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price above the EMA 20 · above the EMA 50

    Week to Nov 13, 2026

  2. 1D daily candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · above the EMA 50

    Daily candle of Nov 19, 2026

  3. 4H 4-hour candles not available

    No value on 4 hours (too few or no checked 4-hour candles).

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
stronger
vs. sector · 3 months
stronger
  • Trend above SMA 200 Price above the 200-day line – above it the long-term trend counts as up; ADX below 20 – hardly any trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility high Typical daily range (ATR 14) above 4% of the price – high.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran stronger.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 19, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 8 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
8 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
8 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 6 of 10 years
  • February: higher in 4 of 10 years
  • March: higher in 4 of 10 years
  • April: higher in 3 of 10 years
  • May: higher in 7 of 10 years
  • June: higher in 6 of 10 years
  • July: higher in 7 of 10 years
  • August: higher in 5 of 10 years
  • September: higher in 6 of 10 years
  • October: higher in 7 of 10 years
  • November (current month): higher in 8 of 10 years
  • December: higher in 6 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January6 of 10
February4 of 10
March4 of 10
April3 of 10
May7 of 10
June6 of 10
July7 of 10
August5 of 10
September6 of 10
October7 of 10
November ●8 of 10
December6 of 10

Through October 2026 (last completed month) · from our daily candles

Fundamental analysis

Revvity · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 24, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 15.6x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
0.0%
dividend per share, average per year
Coverage by free cash flow
15.6x
covered from 1.0x

For you first Valuation

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
1 of 7
criteria with data met
Revenue per year (5 y)
−5.5%
EPS per year (5 y)
−20.4%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
3 of 6
criteria with data met
Net margin
8.4%
Cash flow ÷ profit
2.42x
backed from 1.0

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
mixed
daily candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 28, 2025

Quality 3 of 6 met · 2 without data

  • no data: Gross margin above 40% not stated in the SEC filings
  • not met: Operating margin above 15% 12.5%
  • not met: Net margin above 10% 8.4%
  • not met: Return on equity above 15% 3.3%
  • met: Free cash flow margin above 10% 17.8%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • no data: Free cash flow positive in each of the last 3 fiscal years not stated in the SEC filings
  • met: Equity ratio above 30% 59.6%
Operating margin

12.5% Fiscal year 2025

Rank 42 of 100: higher than 42% of 470 peers (All). medium.

Rank 36 of 100: higher than 36% of 54 peers (Sector). medium.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

8.4% Fiscal year 2025

Rank 37 of 100: higher than 37% of 584 peers (All). medium.

Rank 34 of 100: higher than 34% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

3.3% Fiscal year 2025

Rank 17 of 100: higher than 17% of 544 peers (All). weak.

Rank 14 of 100: higher than 14% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

2.0% Fiscal year 2025 (total assets at year end)

Rank 26 of 100: higher than 26% of 594 peers (All). weak.

Rank 13 of 100: higher than 13% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

59.6% Fiscal year 2025

Rank 84 of 100: higher than 84% of 595 peers (All). strong.

Rank 72 of 100: higher than 72% of 63 peers (Sector). strong.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

17.8% Fiscal year 2025

Rank 69 of 100: higher than 69% of 465 peers (All). strong.

Rank 63 of 100: higher than 63% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

509.4M USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 1 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year −4.8%
  • not met: Over 5 years, revenue grew by more than 5% per year −5.5%
  • not met: Over 10 years, revenue grew by more than 5% per year +2.4%
  • not met: Over 3 years, EPS grew by more than 5% per year −22.8%
  • not met: Over 5 years, EPS grew by more than 5% per year −20.4%
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 3 of 5
  • met: Revenue rose in the last fiscal year +3.7%
Revenue growth 3 years

−4.8% per year

Rank 9 of 100: higher than 9% of 578 peers (All). weak.

Rank 9 of 100: higher than 9% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

−5.5% per year

Rank 2 of 100: higher than 2% of 549 peers (All). weak.

Rank 3 of 100: higher than 3% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+2.4% per year

Rank 19 of 100: higher than 19% of 412 peers (All). weak.

Rank 13 of 100: higher than 13% of 50 peers (Sector). weak.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

−22.8% per year

Rank 10 of 100: higher than 10% of 437 peers (All). weak.

Rank 10 of 100: higher than 10% of 54 peers (Sector). weak.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

−20.4% per year

Rank 3 of 100: higher than 3% of 399 peers (All). weak.

Rank 5 of 100: higher than 5% of 47 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+1.0% per year

Rank 15 of 100: higher than 15% of 375 peers (All). weak.

Rank 12 of 100: higher than 12% of 46 peers (Sector). weak.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 7 met

  • met: Pays a dividend 0.28 USD
  • met: Payout ratio at most 60% of earnings 14%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • not met: Dividend per share higher than 5 years ago 0.0%
  • met: Free cash flow per share covers the dividend 15.6x
  • met: Dividends paid over the last 5 years covered by free cash flow 5% of free cash flow
Payout ratio

14% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

0.0% per year

Rank 6 of 100: higher than 6% of 321 peers (All). weak.

Rank 8 of 100: higher than 8% of 31 peers (Sector). weak.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

15.6x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 5 met · 1 without data

  • no data: Piotroski F-Score at least 7 of 9 too many criteria without data 6 of 8 · 1 without data
  • met: Long-term debt no higher than equity 0.36
  • met: Current assets cover current liabilities 1.68
  • met: Positive equity 7.3B USD
  • met: In 5 years, share count up by at most 5% +4.0%
  • met: Free cash flow positive in the last fiscal year 509.4M USD
Piotroski F-Score

6 of 8 Fiscal year 2025

No rank: not all 9 criteria have data.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.36 at fiscal year end

Rank 73 of 100: lower than 73% of 486 peers (All). strong.

Rank 73 of 100: lower than 73% of 50 peers (Sector). strong.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.68 at fiscal year end

Rank 65 of 100: higher than 65% of 513 peers (All). medium.

Rank 53 of 100: higher than 53% of 63 peers (Sector). medium.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

+4.0% in 5 years

Rank 27 of 100: lower than 27% of 507 peers (All). weak.

Rank 13 of 100: lower than 13% of 59 peers (Sector). weak.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • no data: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light red: Revenue shrank over 5 years (−5.5% per year).
  • Light red: Net income (total) shrank over 5 years (−19.8% per year); per share −20.4% per year.
  • Light yellow: Net margin 8.4%, below the sector median (13.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 4, 2016 – Jan 1, 2017): Revenue 2.1B USD · Net income 234.3M USD · Net margin 11.1%
  2. Fiscal year 2017 (Jan 2, 2017 – Dec 31, 2017): Revenue 2.3B USD · Net income 292.6M USD · Net margin 13.0%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 30, 2018): Revenue 2.8B USD · Net income 237.9M USD · Net margin 8.6%
  4. Fiscal year 2019 (Dec 31, 2018 – Dec 29, 2019): Revenue 2.9B USD · Net income 227.6M USD · Net margin 7.9%
  5. Fiscal year 2020 (Dec 30, 2019 – Jan 3, 2021): Revenue 3.8B USD · Net income 727.9M USD · Net margin 19.2%
  6. Fiscal year 2021 (Jan 4, 2021 – Jan 2, 2022): Revenue 5.1B USD · Net income 943.2M USD · Net margin 18.6%
  7. Fiscal year 2022 (Jan 3, 2022 – Jan 1, 2023): Revenue 3.3B USD · Net income 569.2M USD · Net margin 17.2%
  8. Fiscal year 2023 (Jan 2, 2023 – Dec 31, 2023): Revenue 2.8B USD · Net income 693.1M USD · Net margin 25.2%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 29, 2024): Revenue 2.8B USD · Net income 270.4M USD · Net margin 9.8%
  10. Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Revenue 2.9B USD · Net income 241.2M USD · Net margin 8.4%

Fiscal year 2025 (Dec 30, 2024 – Dec 28, 2025): Revenue 2.9B USD · Net income 241.2M USD · Net margin 8.4%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +4.3% vs. the same quarter a year earlier; grown for 9 quarters in a row.

Revenue 12 months vs. prior 12
+4.6%
12 months: 2.9B USD · Fiscal year 2025: +3.7%
Net margin 12 months
8.6%
Fiscal year 2025: 8.4%
Free cash flow margin 12 months
20.1%
Fiscal year 2025: 17.8%
More depth

Calculation of the 12 months to Oct 4, 2026

  • Revenue: fiscal year to Dec 28, 2025 2.9B USD + year to date to Oct 4, 2026 2.2B USD − same period a year earlier to Sep 28, 2025 2.1B USD = 2.9B USD
  • Net income: fiscal year to Dec 28, 2025 241.2M USD + year to date to Oct 4, 2026 154.8M USD − same period a year earlier to Sep 28, 2025 142.8M USD = 253.2M USD
  • Operating cash flow: fiscal year to Dec 28, 2025 582.9M USD + year to date to Oct 4, 2026 473.9M USD − same period a year earlier to Sep 28, 2025 401.0M USD = 655.8M USD
  • Capital expenditure: fiscal year to Dec 28, 2025 73.5M USD + year to date to Oct 4, 2026 45.2M USD − same period a year earlier to Sep 28, 2025 53.4M USD = 65.4M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 26728.9M+4.3%62.3M8.5%
Apr–Jun 26729.7M+1.3%51.8M7.1%
Jan–Mar 26711.1M+7.0%40.7M5.7%
Oct–Dec 25*772.1M+5.9%98.4M12.7%
Jul–Sep 25698.9M+2.2%46.7M6.7%
Apr–Jun 25720.3M+4.1%53.9M7.5%
Jan–Mar 25664.8M+2.3%42.2M6.4%
Oct–Dec 24*729.4M+4.8%94.6M13.0%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Oct 4, 2026, filed on Nov 10, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is covered.

Cash flow ÷ profit
2.42x
backed from 1.0
Interest coverage
3.9x
well covered from 5 · 3 years: 3.5x
Tax rate
10.6%
for information only · 3 years: 8.5%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 582.9M USD ÷ Net income 241.2M USD = 2.42x
  • Operating income 356.6M USD ÷ Interest expense 92.2M USD = 3.9x
  • Taxes 28.4M USD ÷ profit before tax 268.3M USD = 10.6%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20252.42x3.9x10.6%
20242.32x3.6x10.5%
2023–3.0x1.9%
20221.19x7.1x21.3%
20211.50x24.6x26.3%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and 3 years with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
3 of 10
revenue below the prior year
Net margin range
17.3 percentage points
from 7.9% to 25.2%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+3.7%8.4%
2024+0.2%9.8%
2023−16.9%25.2%
2022−34.6%17.2%
2021+34.0%18.6%
2020+31.2%19.2%
2019+3.8%7.9%
2018+23.1%8.6%
2017+6.7%13.0%
2016−6.5%11.1%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 12.5 USD operating income and 8.4 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue2.9B USD100.0%
Operating income356.6M USD12.5%
Research & development215.8M USD7.6%
Remaining cost of revenue and operating expenses2.3B USD80.0%
Net income241.2M USD8.4%
Interest expense92.2M USD3.2%
Taxes & other (net)23.2M USD0.8%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 25.9% to 12.5%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 47.9% · Operating margin 13.4% · Net margin 11.1%
  2. Fiscal year 2017: Gross margin 47.5% · Operating margin 13.5% · Net margin 13.0%
  3. Fiscal year 2018: Gross margin 48.3% · Operating margin 11.7% · Net margin 8.6%
  4. Fiscal year 2019: Gross margin 48.4% · Operating margin 12.6% · Net margin 7.9%
  5. Fiscal year 2020: Gross margin 55.8% · Operating margin 25.9% · Net margin 19.2%
  6. Fiscal year 2021: Gross margin 48.0% · Operating margin 26.3% · Net margin 18.6%
  7. Fiscal year 2022: Gross margin 60.1% · Operating margin 22.4% · Net margin 17.2%
  8. Fiscal year 2023: Gross margin not available · Operating margin 10.9% · Net margin 25.2%
  9. Fiscal year 2024: Gross margin not available · Operating margin 12.6% · Net margin 9.8%
  10. Fiscal year 2025: Gross margin not available · Operating margin 12.5% · Net margin 8.4%

Returns

Return on equity fell in 5 years from 19.5% to 3.3%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 10.9% · Return on assets 5.5%
  2. Fiscal year 2017: Return on equity 11.7% · Return on assets 4.8%
  3. Fiscal year 2018: Return on equity 9.2% · Return on assets 4.0%
  4. Fiscal year 2019: Return on equity 8.1% · Return on assets 3.5%
  5. Fiscal year 2020: Return on equity 19.5% · Return on assets 9.1%
  6. Fiscal year 2021: Return on equity 13.2% · Return on assets 6.3%
  7. Fiscal year 2022: Return on equity 7.7% · Return on assets 4.0%
  8. Fiscal year 2023: Return on equity 8.8% · Return on assets 5.1%
  9. Fiscal year 2024: Return on equity 3.5% · Return on assets 2.2%
  10. Fiscal year 2025: Return on equity 3.3% · Return on assets 2.0%

Equity and long-term debt

The equity ratio rose in 5 years from 46.9% to 59.6%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 2.2B USD · Long-term debt 1.0B USD
  2. Fiscal year 2017: Equity 2.5B USD · Long-term debt 1.8B USD
  3. Fiscal year 2018: Equity 2.6B USD · Long-term debt 1.9B USD
  4. Fiscal year 2019: Equity 2.8B USD · Long-term debt 2.1B USD
  5. Fiscal year 2020: Equity 3.7B USD · Long-term debt 1.6B USD
  6. Fiscal year 2021: Equity 7.1B USD · Long-term debt 5.0B USD
  7. Fiscal year 2022: Equity 7.4B USD · Long-term debt 3.9B USD
  8. Fiscal year 2023: Equity 7.9B USD · Long-term debt 3.2B USD
  9. Fiscal year 2024: Equity 7.7B USD · Long-term debt 3.2B USD
  10. Fiscal year 2025: Equity 7.3B USD · Long-term debt 2.6B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 1.36 to 1.68.

Current ratio
  1. Fiscal year 2016: Current ratio 1.97
  2. Fiscal year 2017: Current ratio 1.26
  3. Fiscal year 2018: Current ratio 1.60
  4. Fiscal year 2019: Current ratio 1.80
  5. Fiscal year 2020: Current ratio 1.36
  6. Fiscal year 2021: Current ratio 2.01
  7. Fiscal year 2022: Current ratio 2.13
  8. Fiscal year 2023: Current ratio 2.07
  9. Fiscal year 2024: Current ratio 3.60
  10. Fiscal year 2025: Current ratio 1.68

Cash flow

Free cash flow fell in 5 years from 814.7M USD to 509.4M USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 350.6M USD · Capital expenditure 31.7M USD · Free cash flow 318.9M USD
  2. Fiscal year 2017: Operating cash flow 288.5M USD · Capital expenditure 39.1M USD · Free cash flow 249.4M USD
  3. Fiscal year 2018: Operating cash flow 311.0M USD · Capital expenditure 93.3M USD · Free cash flow 217.8M USD
  4. Fiscal year 2019: Operating cash flow 363.5M USD · Capital expenditure 76.3M USD · Free cash flow 287.1M USD
  5. Fiscal year 2020: Operating cash flow 892.2M USD · Capital expenditure 77.5M USD · Free cash flow 814.7M USD
  6. Fiscal year 2021: Operating cash flow 1.4B USD · Capital expenditure 99.9M USD · Free cash flow 1.3B USD
  7. Fiscal year 2022: Operating cash flow 679.8M USD · Capital expenditure 85.6M USD · Free cash flow 594.2M USD
  8. Fiscal year 2023: Operating cash flow not available · Capital expenditure 81.4M USD · Free cash flow not available
  9. Fiscal year 2024: Operating cash flow 628.3M USD · Capital expenditure 86.6M USD · Free cash flow 541.7M USD
  10. Fiscal year 2025: Operating cash flow 582.9M USD · Capital expenditure 73.5M USD · Free cash flow 509.4M USD

Share count

The share count rose in 5 years by 4.0% – more new shares were issued than repurchased (dilution).

Diluted share count
  1. Fiscal year 2016: Diluted share count 110.3M
  2. Fiscal year 2017: Diluted share count 110.9M
  3. Fiscal year 2018: Diluted share count 111.5M
  4. Fiscal year 2019: Diluted share count 111.5M
  5. Fiscal year 2020: Diluted share count 112.1M
  6. Fiscal year 2021: Diluted share count 116.7M
  7. Fiscal year 2022: Diluted share count 126.4M
  8. Fiscal year 2023: Diluted share count 124.8M
  9. Fiscal year 2024: Diluted share count 122.8M
  10. Fiscal year 2025: Diluted share count 116.6M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Dividend per share

The dividend per share stayed roughly the same in 5 years (0.28 USD).

RVTY USD per share
  1. Fiscal year 2016: RVTY 0.28 USD
  2. Fiscal year 2017: RVTY 0.28 USD
  3. Fiscal year 2018: RVTY 0.28 USD
  4. Fiscal year 2019: RVTY 0.28 USD
  5. Fiscal year 2020: RVTY 0.28 USD
  6. Fiscal year 2021: RVTY 0.28 USD
  7. Fiscal year 2022: RVTY 0.28 USD
  8. Fiscal year 2023: RVTY 0.28 USD
  9. Fiscal year 2024: RVTY 0.28 USD
  10. Fiscal year 2025: RVTY 0.28 USD

Payout ratio (earnings)

The payout ratio rose in 5 years from 4.3% to 13.5%.

RVTY
  1. Fiscal year 2016: RVTY 13.2%
  2. Fiscal year 2017: RVTY 10.6%
  3. Fiscal year 2018: RVTY 13.1%
  4. Fiscal year 2019: RVTY 13.7%
  5. Fiscal year 2020: RVTY 4.3%
  6. Fiscal year 2021: RVTY 3.5%
  7. Fiscal year 2022: RVTY 6.2%
  8. Fiscal year 2023: RVTY 5.0%
  9. Fiscal year 2024: RVTY 12.7%
  10. Fiscal year 2025: RVTY 13.5%

Payout ratio (free cash flow)

The payout ratio (free cash flow) rose in 5 years from 3.8% to 6.4%.

RVTY
  1. Fiscal year 2016: RVTY 9.7%
  2. Fiscal year 2017: RVTY 12.3%
  3. Fiscal year 2018: RVTY 14.2%
  4. Fiscal year 2019: RVTY 10.8%
  5. Fiscal year 2020: RVTY 3.8%
  6. Fiscal year 2021: RVTY 2.5%
  7. Fiscal year 2022: RVTY 5.9%
  8. Fiscal year 2023: RVTY not available
  9. Fiscal year 2024: RVTY 6.4%
  10. Fiscal year 2025: RVTY 6.4%

Source: SEC filings, fiscal years up to Dec 28, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 15.6x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
0.0%
dividend per share, average per year
Coverage by free cash flow
15.6x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 0.28 USD → fiscal year 2025 0.28 USD = 0.0% per year
  • Free cash flow per share 4.37 USD ÷ dividend per share 0.28 USD = 15.6x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
0.28 USD · Fiscal year 2025
Dividend growth per year
3 y 0.0%5 y 0.0%10 y 0.0%
Payout ratio
of earnings 14% of free cash flow 6%
To shareholders (5 years)
1.9B USD 91% through repurchases
Share count over 5 years
+4.0% more shares – dilution

Dividend per share

The dividend per share stayed roughly the same in 5 years (0.28 USD).

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 0.28 USD
  2. Fiscal year 2017: Dividend per share 0.28 USD
  3. Fiscal year 2018: Dividend per share 0.28 USD
  4. Fiscal year 2019: Dividend per share 0.28 USD
  5. Fiscal year 2020: Dividend per share 0.28 USD
  6. Fiscal year 2021: Dividend per share 0.28 USD
  7. Fiscal year 2022: Dividend per share 0.28 USD
  8. Fiscal year 2023: Dividend per share 0.28 USD
  9. Fiscal year 2024: Dividend per share 0.28 USD
  10. Fiscal year 2025: Dividend per share 0.28 USD

Payout ratios

The payout ratio rose in 5 years from 4.3% to 13.5%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 13.2% · Payout ratio (free cash flow) 9.7%
  2. Fiscal year 2017: Payout ratio (earnings) 10.6% · Payout ratio (free cash flow) 12.3%
  3. Fiscal year 2018: Payout ratio (earnings) 13.1% · Payout ratio (free cash flow) 14.2%
  4. Fiscal year 2019: Payout ratio (earnings) 13.7% · Payout ratio (free cash flow) 10.8%
  5. Fiscal year 2020: Payout ratio (earnings) 4.3% · Payout ratio (free cash flow) 3.8%
  6. Fiscal year 2021: Payout ratio (earnings) 3.5% · Payout ratio (free cash flow) 2.5%
  7. Fiscal year 2022: Payout ratio (earnings) 6.2% · Payout ratio (free cash flow) 5.9%
  8. Fiscal year 2023: Payout ratio (earnings) 5.0% · Payout ratio (free cash flow) not available
  9. Fiscal year 2024: Payout ratio (earnings) 12.7% · Payout ratio (free cash flow) 6.4%
  10. Fiscal year 2025: Payout ratio (earnings) 13.5% · Payout ratio (free cash flow) 6.4%

What goes back to shareholders

Over 5 years, 1.9B USD went back to shareholders, 91% of it through share repurchases.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 30.8M USD · Share repurchases 151.8M USD · New shares issued (including employee plans) not available · Free cash flow 318.9M USD
  2. Fiscal year 2017: Dividends paid 30.8M USD · Share repurchases 3.8M USD · New shares issued (including employee plans) not available · Free cash flow 249.4M USD
  3. Fiscal year 2018: Dividends paid 31.0M USD · Share repurchases 57.4M USD · New shares issued (including employee plans) not available · Free cash flow 217.8M USD
  4. Fiscal year 2019: Dividends paid 31.1M USD · Share repurchases 6.3M USD · New shares issued (including employee plans) not available · Free cash flow 287.1M USD
  5. Fiscal year 2020: Dividends paid 31.2M USD · Share repurchases 6.9M USD · New shares issued (including employee plans) not available · Free cash flow 814.7M USD
  6. Fiscal year 2021: Dividends paid 32.4M USD · Share repurchases 73.1M USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  7. Fiscal year 2022: Dividends paid 35.3M USD · Share repurchases 80.6M USD · New shares issued (including employee plans) not available · Free cash flow 594.2M USD
  8. Fiscal year 2023: Dividends paid 35.0M USD · Share repurchases 388.9M USD · New shares issued (including employee plans) not available · Free cash flow not available
  9. Fiscal year 2024: Dividends paid 34.5M USD · Share repurchases 369.6M USD · New shares issued (including employee plans) not available · Free cash flow 541.7M USD
  10. Fiscal year 2025: Dividends paid 32.8M USD · Share repurchases 820.8M USD · New shares issued (including employee plans) not available · Free cash flow 509.4M USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Revvity next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison RVTY, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
RVTY Revvity this stock 2.9B USD −5.5%–12.5%8.4%3.3%59.6%17.8%–
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
NVAX Novavax 1.1B USD +18.8%93.5%40.3%39.2%–−10.9%−22.3%5/9
Median of the sector 27 symbols 44.3B USD +8.4%67.6%17.8%13.2%13.6%38.5%15.8%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector RVTY next to MRNA – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light red: shrinking

−5.5% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it fell by 5.5% per year on average. The median company in the sector reached +8.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−19.8% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: −20.4% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 19.8% per year on average. The median company in the sector reached +5.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

8.4% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 8.45 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 19.2%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.36 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.36 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

14% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.14 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
2.9B USD
Revenue vs. prior year
+3.7%
Net income (FY)
241.2M USD
Net income vs. prior year
−10.8%
EPS (FY)
2.07 USD
Superinvestors holding
1 of 26
Fiscal year to Dec 28, 2025 · 10-K filed Feb 24, 2026 · Balance sheet Oct 4, 2026 (filed Nov 10, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 28, 2025 2.9B241.2M 8.4% 2.07 0.28 14%
2024Dec 29, 2024 2.8B270.4M 9.8% 2.20 0.28 13%
2023Dec 31, 2023 2.8B693.1M 25.2% 5.55 0.28 5%
2022Jan 1, 2023 3.3B569.2M 17.2% 4.50 0.28 6%
2021Jan 2, 2022 5.1B943.2M 18.6% 8.08 – –
2020Jan 3, 2021 3.8B727.9M 19.2% 6.49 0.28 4%
2019Dec 29, 2019 2.9B227.6M 7.9% 2.04 0.28 14%
2018Dec 30, 2018 2.8B237.9M 8.6% 2.13 0.28 13%
2017Dec 31, 2017 2.3B292.6M 13.0% 2.64 0.28 11%
2016Jan 1, 2017 2.1B234.3M 11.1% 2.12 0.28 13%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Oct 4, 2026 728.9M62.3M 8.5% 0.56 0.07 13%
Q2/26Jul 5, 2026 729.7M51.8M 7.1% 0.47 0.07 15%
Q1/26Apr 5, 2026 711.1M40.7M 5.7% 0.36 0.07 19%
Q4/25*Dec 28, 2025 772.1M98.4M 12.7% – 0.07 –
Q3/25Sep 28, 2025 698.9M46.7M 6.7% 0.40 0.07 18%
Q2/25Jun 29, 2025 720.3M53.9M 7.5% 0.46 0.07 15%
Q1/25Mar 30, 2025 664.8M42.2M 6.4% 0.35 0.07 20%
Q4/24*Dec 29, 2024 729.4M94.6M 13.0% – 0.07 –
Q3/24Sep 29, 2024 684.0M94.4M 13.8% 0.77 0.07 9%
Q2/24Jun 30, 2024 691.7M55.4M 8.0% 0.45 0.07 16%
Q1/24Mar 31, 2024 649.9M26.0M 4.0% 0.21 0.07 33%
Q4/23*Dec 31, 2023 695.9M78.6M 11.3% – 0.07 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $1.3M3 people −$1.3M
6 months $00 people $1.3M3 people −$1.3M
12 months $00 people $6.0M7 people −$6.0M

Latest transactions

  • Oct 1, 2026 Gonzales Anita Officer Open-market sale · 10b5-1 plan 84 shares · $13.1K · SEC
  • Sep 21, 2026 Krakowiak Maxwell Officer Open-market sale · 10b5-1 plan 1,631 shares · $235.7K · SEC
  • Sep 16, 2026 Vohra Tajinder S Officer Open-market sale · 10b5-1 plan 7,330 shares · $1.0M · SEC
  • Jul 20, 2026 Gonzales Anita Officer Open-market sale · 10b5-1 plan 85 shares · $9.3K · SEC
  • Apr 20, 2026 Gonzales Anita Officer Open-market sale · 10b5-1 plan 80 shares · $7.4K · SEC
  • Feb 24, 2026 Victor Miriame Officer Open-market sale · 10b5-1 plan 1,862 shares · $180.9K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Revvity?

All superinvestor portfolios

1 of 26 tracked superinvestors reports a position.

Superinvestors with a position in Revvity, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Bridgewater Associates 0.1% +723.6% increased Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on RVTY yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: RVTY

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close